Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug

Soleno Therapeutics brings Neurocrine Biosciences Vykat XR, a drug commercialized for treating the rare genetic disease Prader-Willi syndrome. This blockbuster prospect complements Crenessity, a Neurocrine drug approved for treating a rare endocrine disorder called congenital adrenal hyperplasia. The post Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug appeared first on MedCity…

Read More

Building Patient Trust in Digital Health Software

We need apps that have been tested with real users to ensure they are intuitive and easy to use. The apps also need to be designed to be inclusive of different needs including patients with disabilities, different levels of tech literacy, and diverse needs.  The post Building Patient Trust in Digital Health Software appeared first…

Read More

Navigating the Path to Success in Medical Devices: Strategy, Reimbursement, and Competition  

The keys are establishing a culture that applauds ideas and learns from “failures” rather than seeking to place blame, recognizing that the best ideas can come from any source, and benefiting from cross-functional discussion and challenge. The post Navigating the Path to Success in Medical Devices: Strategy, Reimbursement, and Competition   appeared first on MedCity News.

Read More

Turning CMS’ Guidelines into a SNF Playbook

These updated guidelines are a good opportunity for SNFs to change how they operate moving forward. Those who start implementing new policies and objectives soon and begin to operate as one system, rather than prioritizing each outcome separately, will be the ones to see the greatest results. The post Turning CMS’ Guidelines into a SNF…

Read More